STOCK TITAN
  1. Home
  2. News
  3. APLS

Apellis Pharmaceuticals Inc - APLS STOCK NEWS

IMPACT
SENTIMENT
APLS : Nasdaq
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
conferences clinical trial
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
fda approval
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
conferences
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
conferences
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
IMPACT
SENTIMENT
APLS : Nasdaq
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
Stock APLS logo
Apellis Pharmaceuticals Inc
Nasdaq:APLS

APLS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.